CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • INBX Dashboard
  • Financials
  • Filings
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • 8-K Filing

Inhibrx (INBX) 8-KInhibrx Reports Second Quarter 2021 Financial Results

Filed: 9 Aug 21, 4:12pm
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 8-K Current report
    • 99.1 Inhibrx Reports Second Quarter 2021 Financial Results
    • Download Excel data file
    • View Excel data file
    INBX similar filings
    • 28 Oct 21 Departure of Directors or Certain Officers
    • 12 Oct 21 Regulation FD Disclosure
    • 3 Sep 21 Entry into a Material Definitive Agreement
    • 9 Aug 21 Inhibrx Reports Second Quarter 2021 Financial Results
    • 21 Jun 21 Entry into a Material Definitive Agreement
    • 9 Jun 21 Submission of Matters to a Vote of Security Holders
    • 13 May 21 Inhibrx Reports First Quarter 2021 Financial Results
    Filing view
    Share this filing

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549  
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): August 9, 2021
    INHIBRX, INC.
    (Exact name of registrant as specified in its charter)  
    Delaware001-3945282-4257312
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    11025 N. Torrey Pines Road, Suite 200
    La Jolla, CA 92037
    (Address of Principal Executive Offices and Zip Code)
    Registrant’s telephone number, including area code: (858) 795-4220
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company  ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒




    Item 2.02    Results of Operations and Financial Condition
    On August 9, 2021, Inhibrx, Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2021. A copy of the press release is furnished as Exhibit 99.1 to this report.

    The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
    Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits.
    Exhibit No.Description
    99.1
    Press Release issued by Inhibrx, Inc. on August 9, 2021

    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Date: August 9, 2021
    INHIBRX, INC.
    By:/s/ Kelly Deck
    Name:Kelly Deck
    Title:Chief Financial Officer


    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn